# Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year

> **NCT02889809** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 477 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Fluticasone furoate
- **DRUG:** Placebo
- **DRUG:** Montelukast
- **DRUG:** Short Acting Beta 2 Agonist

## Key facts

- **NCT ID:** NCT02889809
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-10
- **Primary completion:** 2021-04-09
- **Final completion:** 2021-06-04
- **Target enrollment:** 477 (ACTUAL)
- **Last updated:** 2024-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02889809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02889809, "Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02889809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*